| Literature DB >> 18489499 |
Jeroen P Jansen1, Bruce Crawford, Gert Bergman, Wiro Stam.
Abstract
Recently, mixed treatment comparisons (MTC) have been presented as an extension of traditional meta-analysis by including multiple different pairwise comparisons across a range of different interventions. MTC allow for indirect comparisons and can therefore provide very useful information for clinical and reimbursement decision-making in the absence of head-to-head data. In this article, we provide an introductory overview of MTC illustrated with example analyses of different drug treatments in rheumatoid arthritis using a continuous patient-reported end point. As a background, we start with an overview of the traditional meta-analyses for pairwise trials, and the difference between a traditional approach and a Bayesian approach. Next, the Bayesian MTC for continuous outcomes are presented. We finish with a discussion of how MTC can best be presented in order to maximize acceptance by target audiences, i.e., clinicians and market access decision-makers.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18489499 DOI: 10.1111/j.1524-4733.2008.00347.x
Source DB: PubMed Journal: Value Health ISSN: 1098-3015 Impact factor: 5.725